Skip to main content
Premium Trial:

Request an Annual Quote

Morphotek Earns $10 million in Second-Round Financing

NEW YORK, Aug. 13 – Evolution acceleration company Morphotek received $10 million in second-round funding from lead investor Applied Genomic Technology Capital Funds and others, the company announced on Monday.

Philadelphia-based Morphotek, which is developing technology to create new varieties of proteins, cells, plants, and animals with commercially valuable traits, plans to use the additional funding to expand overall operations, including hiring additional employees and increasing the efforts in its antibody-based therapeutic and agriculture programs.

“Morphotek's technology harnesses the power of evolution to improve the function of a single gene, or of many genes at once, and does not require advanced knowledge of which genes to choose," David Stone, a partner at AGTC Funds, said in a statement. "This offers significant advantages over other methods of applied evolution, and should enable Morphotek to develop a wide range of valuable products.”   

Other investors included Burrill & Co. and CB Healthcare Ventures. Existing investors include Tonbridge Capital and Trieste Investment Group.

Morphotek was founded in May 2000 by CEO Nicholas Nicolaides, COO Philip Sass, and Vice President of Research and Development Luigi Grasso.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.